Research programme: periodontitis therapy - OraPharma
Alternative Names: Periodontitis therapy research programme - OraPharmaLatest Information Update: 11 Oct 2006
At a glance
- Originator OraPharma; University of North Carolina at Chapel Hill
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Periodontal disorders
Most Recent Events
- 18 Feb 2003 OraPharma has been acquired by Johnson & Johnson
- 23 Jan 2003 This programme is still in active development
- 23 Jan 2003 Phase-I clinical trials in Periodontal disorders in USA (unspecified route)